[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-tumor-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-tumor-adult":694},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,50,78,105,127,157,177,205,228,264,290,310,336,364,397,415,436,474,504,536,562,597,620,644,664],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053818",false,"NCT07699172","EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors","A Prospective Single-Arm Study of EEG-Based Neural Signal Decoding for Cognitive Function Preservation in Patients Undergoing Brain Tumor Surgery","Inclusion Criteria:\n\n* Age 18 years to 75 years.\n* Patients diagnosed with brain glioma and scheduled for surgical treatment.\n* Conscious and able to understand study procedures.\n* Able to complete neuropsychological assessments.\n* Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe dysfunction of major organs (heart, lung, liver, or kidney).\n* Severe psychiatric disorders or cognitive impairment.\n* Severe language impairment preventing completion of study procedures.\n* Any other condition judged by the investigator to make participation inappropriate.","ALL","18 Years","75 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor surgery. Participants will undergo standardized neuropsychological assessments together with preoperative, intraoperative, and postoperative electrophysiological recordings. The study will investigate whether EEG-based neural decoding can improve objective cognitive function assessment and support individualized functional preservation during brain tumor surgery.",[27,28,29],"Glioma","Brain Neoplasm","Brain Tumor Adult",[31,32,33,34,35,36],"Electroencephalography","EEG","Neural Signal Decoding","Cognitive Function","Cognitive Preservation","Brain Tumor Surgery","NOT_YET_RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2028-07-31",{"name":47,"class":48},"Bo Wang","OTHER",1,{"id":51,"slug":4,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100590038","NCT06962215","The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON)","The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery","IPSIMANON","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patient covered by a social security scheme\n* Patient signed informed consent form\n* Patient found to have a brain tumor (potentially malignant, primary or secondary if this is the mode of entry into the disease)\n* Hospitalization in the Neurosurgery Department at the time of tumor discovery, before the histological diagnosis is announced.\n\nExclusion Criteria:\n\n* Patients with a personal history of cancer\n* Patient without family AND unable to receive information",{"count":58,"type":21},250,[24],"The goal of this clinical trial is to demonstrate that simulation training for paramedical staff in neurosurgery departments, in announcing and accompanying patients with a brain tumor, improves patient satisfaction when a (potentially malignant) brain tumor is discovered, compared with usual care.\n\nThe main question it aims to answer is:\n\n\\- Are patients more satisfied (as measured by scores on the EORCT IN-PATSAT32 questionnaire) with their neurosurgical hospitalization following the discovery of a brain tumor in centers where paramedics have been trained by simulation?\n\nResearchers will compare the results of the EORTC IN-PATSAT32 questionnaire to determine whether paramedic training improves patient satisfaction between simulation-trained and untrained centers.\n\nParticipants will be asked to complete the EORT IN-PATSAT32 questionnaire at the end of their hospital stay.",[29],[63,64,65,66],"Brain tumor","Simulation Training","Paramedical","Neurosurgery","RECRUITING","2026-06-19",{"date":70,"type":41},"2026-06-23",{"date":72,"type":41},"2025-05-15",{"date":74,"type":21},"2027-10",{"name":76,"class":48},"University Hospital, Brest",11,{"id":79,"slug":4,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":49},"100642670","NCT07650994","Movie-Watching Functional MRI for Mapping Brain Function in Neurosurgical Patients","Naturalistic Neuroimaging for Neurosurgical Brain Mapping","Inclusion Criteria:\n\n* Any sex, age between 21 to 70 years;\n* Known or suspected glioma (lesion) of the brain;\n* English speaking;\n* Patients with clinical fMRI scheduled (or pending scheduling) for presurgical planning at BWH ordered by a BWH clinician;\n* Passes prescreening and standard of care screenings for 3 Tesla MRI;\n* Willing to participate in the additional study scan and neuropsychological assessment visit;\n* Informed consent form signed by the subject or legally acceptable representative.\n\nExclusion Criteria:\n\n* Contraindications to MRI: Note: MRI screening will be performed by radiology staff as part of their standard process for their clinical scans and if subjects do not pass the screen, MRI will not be performed.\n* Pregnancy or possible pregnancy: Female participants under 55 (or 45 with menstrual cycle in the past 12 months) who may be pregnant. Per policy: potential subjects will be asked if they are pregnant and excluded if they say yes. If unsure, pregnancy testing will be performed. Any subjects with positive result will be excluded.","21 Years","70 Years",{"count":87,"type":21},90,[24],"This research will compare a new type of functional MRI (fMRI) called naturalistic viewing (also called movie watching) to standard clinical fMRI techniques. Standard clinical fMRI currently uses multiple tasks such as reading and responding to words or sentences to determine which areas of the brain are responsible for language. Surgeons can use this information to help plan brain surgeries. This research will help determine if the movie-watching fMRI is equivalent or better than the standard task-based fMRI. If so, it could be useful for planning patients' surgeries in the future, without the need for multiple tasks.",[27,29],[92,93,94,95],"Movie Functional Magnetic Resonance Imaging","Clinical Functional Magnetic Resonance Imaging","Presurgical Planning","Presurgical Brain Mapping","2026-06-17",{"date":98,"type":41},"2026-06-22",{"date":100,"type":21},"2026-09-01",{"date":102,"type":21},"2029-03-31",{"name":104,"class":48},"Brigham and Women's Hospital",{"id":106,"slug":4,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":49},"100636807","NCT07570485","Feasibility Assessment of Adapted Physical Activity in Patients Treated for a Brain Tumor","APATC","Inclusion Criteria:\n\n* Men or women ≥ 18 years old,\n* Receiving medical oncology treatment at the CLCC Eugène Marquis,\n* Diagnosed with a primary brain tumour, regardless of diagnosis, grade or treatment,\n* Possible motor, sensory, attention, concentration, or memory deficits,\n* Patients who accept the general terms of use for connected watches\n* Patients affiliated with or covered by the French social security system,\n* Patients who have received information and signed informed consent (or their legal representative),\n\nExclusion Criteria:\n\n* WHO score ≥ 3\n* Comprehension disorders that prevent participation in adapted physical activity\n* Pregnant or breastfeeding women\n* Patients without the necessary devices to use a smartwatch (smartphone, tablet or computer),\n* Patients deprived of liberty, under guardianship, or curatorship, or subject to any other administrative safeguard measure.\n\nPatients unable to comply with the study schedule for social, medical, or psychological reasons.",{"count":87,"type":21},[24],"The goal of this clinical trial is to assess the feasibility of an adapted physical activity (APA) program in adult patients (≥18 years) with primary brain tumors, regardless of tumor type, grade, treatment stage, or the presence of motor, sensory, attention, concentration, or memory deficits.\n\nThe main question it aims to answer is:\n\nWhat is the effective adherence rate to an APA program among eligible patients with primary brain tumors?\n\nAdditional questions include:\n\n* What is the observance rate (number of sessions completed, intensity achieved, and duration) during the 3-month supervised APA program?\n* What is the retention rate (proportion of patients completing the program and continuing APA beyond the initial period)?\n* What is the impact of APA on quality of life, anxiety-depression, and cancer-related symptoms (measured via QLQ-BN20, HADS, and MFI-20 questionnaires at baseline, 3, and 4 months)?\n\nParticipants will:\n\n* Undergo a 3-month supervised APA program (with possible continuation beyond this period).\n* Use connected watches to monitor physical activity (if they accept the general conditions of use).\n* Complete self-questionnaires (IPAQ, BREQ-2, QPP, QLQ-BN20, HADS, MFI-20) at inclusion, 3 months, and 4 months.\n* Be followed for a total of 4 months after inclusion.",[29],[116,117],"Brain Tumor","Adapted physical activity (APA)","2026-06-10",{"date":120,"type":41},"2026-06-12",{"date":122,"type":21},"2026-06-01",{"date":124,"type":21},"2028-06-01",{"name":126,"class":48},"Center Eugene Marquis",{"id":128,"slug":4,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":49},"100302121","NCT03213002","Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM","Phase I\u002FII Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)","CAPTEM","Inclusion Criteria:\n\n1. Be capable of giving informed consent.\n2. Have a pathology proven diagnosis of any of newly diagnosed Glioblastoma Multiforme WHO IV\n3. Have completed the first part of standard of care chemo-radiation (Stupp), for 6 weeks, and not started the maintenance phase of temozolomide\n4. Agree to use effective barrier contraception while on treatment and for 2 months thereafter, if of childbearing potential\n5. Have a life expectancy \\> 3 months\n6. Be between the ages of 18 to 74\n7. Have a performance status KPS 70 or greater\n8. Be able to swallow pills and capsules\n9. Be able to tolerate oral chemotherapeutic medications, with no health threatening allergies or side effects, based on lab and clinical findings\n10. Have adequate bone marrow function, liver function and renal function before commencing therapy\n\nExclusion Criteria:\n\n1. Prior chemotherapy with capecitabine or temozolomide for other prior malignancies. Patients previously treated with continuous infusion 5-FU or any schedule of DTIC, which are similar to capecitabine and temozolomide, respectively, will be excluded.\n2. Prior chemotherapies for newly diagnosed GBM or AA, other than temozolomide during radiation.\n3. Patients with a history of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide (i.e. anaphylaxis or anaphylactic reactions),\n4. Serious medical or psychiatric illness preventing informed consent or treatment (e.g., serious infection)\n5. Prior malignancies in the last 5 years other than curatively treated carcinoma in-situ previously treated with curative intent (cancer free for the past one year).\n6. Performance status, KPS \\\u003C 70\n7. Inability to swallow pills and capsules\n8. Concurrent chemotherapy or treatment for the active disease, including devices such as Optune, high dose vitamin supplements, or any other chemotherapy\n9. Patients taking concomitant medications such as Coumadin and phenytoin medications, need to be excluded because of interactions with capecitabine\n10. Patients with previously documented CAD will need to be evaluated by cardiology prior to start to help risk stratify for capecitabine tolerance\n11. Patients with renal insufficiency or hepatic insufficiency\n12. Patients with coagulopathies\n13. Women who are pregnant or lactating.","74 Years",{"count":136,"type":21},67,[138,139],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM).\n\nCapecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg\u002Fm2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.",[142,143,144,145,116,146,29,147,148],"Glioblastoma Multiforme (GBM)","Glioblastoma","Glioma of Brain","Glioblastoma, Adult","Brain Tumor, Primary","Cancer","Brain Cancer","2026-05-28",{"date":122,"type":41},{"date":152,"type":41},"2017-06-13",{"date":154,"type":21},"2029-06",{"name":156,"class":48},"Northwell Health",{"id":158,"slug":4,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":49},"100610352","NCT07226466","Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer","Inclusion Criteria:\n\n1. \\>= 18 years old\n2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.\n3. Diagnosis of primary solid tumor and secondary involvement of the brain\n4. If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none \\> 1 cm in max diameter.\n5. Candidate for standard of care \u002F usual care (SOC) focused brain radiotherapy.\n6. No prior brain radiotherapy, including whole brain radiotherapy.\n7. Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.\n8. Estimated life expectancy post-treatment of \\> 2 years.\n\nExclusion Criteria:\n\n1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).\n2. Diagnosis of memory disorder pre-treatment.\n3. Leptomeningeal disease or disease involving either hippocampus.",{"count":163,"type":21},40,"OBSERVATIONAL","This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.",[29,167,146,116],"Brain Metastases From Solid Tumors","2026-05-20",{"date":170,"type":41},"2026-05-22",{"date":172,"type":21},"2026-07-01",{"date":174,"type":21},"2028-10-31",{"name":176,"class":48},"University of California, San Francisco",{"id":178,"slug":4,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":49},"100624758","NCT07413796","Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures","Prospective Randomized Controlled Trial of Skin Closure Techniques in Oncological Cranial Neurosurgery: Interrupted Transdermal Sutures and Running Intradermal Suture.","NEURO-SUTURE","Inclusion Criteria:\n\n* Male or female at least 18 years old\n* Qualified for a craniotomy due to supratentorial intracranial tumor\n\nExclusion Criteria:\n\n* Revision surgery due to recurrent brain tumor\n* Emergency neurosurgical procedure\n* Scalp incision involving glabrous skin (e.g. forehead) or facial regions (e.g. eyebrow)",{"count":185,"type":21},382,[24],"The purpose of this study is to compare two commonly used methods of closing the skin after surgery for an intracranial tumor. Skin closure is one of the most important steps in neurosurgical procedures, as it has a major influence on how well the wound heals. In patients with brain tumors, proper wound healing is especially important because it may affect how soon additional treatments, such as radiotherapy or chemotherapy, can be started.\n\nThere are different ways to close the skin after surgery, including running sutures and interrupted sutures. Both methods are widely used and considered safe. However, in oncological neurosurgery, there is limited scientific evidence comparing their effects, and the choice of technique is often based on the surgeon's personal experience. In this study, investigators will compare skin closure using running absorbable sutures with interrupted non-absorbable sutures. Investigators will evaluate how well, depending on used suturing methods, the wound heals and how often wound-related complications occur, such as infection, separation of the wound edges, or leakage of cerebrospinal fluid. Investigators believe that the results of this study will help improve wound care in patients undergoing neurosurgical treatment for brain tumors and, as a result, may contribute to better recovery and overall quality of life.",[29,189,190,27,143],"Brain Tumor Benign","Meningioma",[192,193,194,195,196],"skin closure","brain tumor","intracranial tumor","glioma","meningioma","2026-05-19",{"date":168,"type":41},{"date":200,"type":41},"2026-02-01",{"date":202,"type":21},"2028-05",{"name":204,"class":48},"Medical University of Warsaw",{"id":206,"slug":4,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":164,"phases":4,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":49},"100624596","NCT07411690","Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors","Cerebrospinal Fluid Leak Incidence, Management and Risk Factor After Supratentorial Craniotomy for Intracranial Tumors: a Prospective Observational Study.","CSF-IMR","Inclusion Criteria:\n\n* Male or female at least 18 years old\n* Qualified for a craniotomy due to supratentorial intracranial tumor\n\nExclusion Criteria:\n\n* Revision surgery due to recurrent brain tumor\n* Emergency neurosurgical procedure",{"count":213,"type":21},200,"6 Weeks","Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura) to reach the tumor. At the end of the operation, this covering is carefully closed again. In some cases, the closure might not be completely adequate leading to cerebrospinal fluid leak. This leakage may collect under the scalp or flow out through the surgical wound. When this happens, the surgical wound may not heal properly, and the risk of infection can increase. These complications can delay recovery and may postpone additional treatments, such as radiotherapy or chemotherapy, that are often needed after brain tumor surgery. Although cerebrospinal fluid leakage is less common after supratentorial craniotomy (surgery on the upper part of the brain) than after other types of brain surgery, it remains a challenging complication and has not been well studied in this group of patients. The aim of this study is to determine how often cerebrospinal fluid leakage occurs after supratentorial craniotomy for intracranial tumors, identify factors that increase the risk of leakage, and evaluate how these leaks are managed. Understanding these factors may help reduce the occurrence of cerebrospinal fluid leakage and improve postoperative recovery in the future.",[29,189,217,218,143,27,190],"CerebroSpinal Fluid (CSF) Leak","Craniotomy",[194,220,221,195,196],"cerebrospinal fluid leak","supratentorial craniotomy",{"date":170,"type":41},{"date":224,"type":41},"2026-02-03",{"date":226,"type":21},"2028-04",{"name":204,"class":48},{"id":229,"slug":4,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":245,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":49},"100638098","NCT07590726","PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors","PIRe","Inclusion Criteria\n\n* Primary relative of an adult diagnosed with acquired brain injury (ABI) or malignant brain tumor (MBT), admitted to a participating hospital department.\n* Formally identified as the primary relative by the patient.\n* Aged ≥18 years.\n* Ability to read, understand, and complete questionnaires in Danish.\n\nExclusion Criteria\n\n* Insufficient proficiency in Danish to complete questionnaires and participate in structured conversations.\n* Concurrent participation in another interventional study with a similar aim that may interfere with the present study.",{"count":235,"type":21},160,[24],"Serious brain diseases and injuries affect not only the person who becomes ill or injured, but also their family. Relatives of people with acquired brain injury (ABI) or malignant brain tumor (MBT) often take on a major role in daily care, decision-making, and coordination across healthcare services. This role can include managing information, supporting rehabilitation, and acting as a link between hospital care and community rehabilitation. Many relatives report high levels of stress, uncertainty, and emotional burden, especially during transitions between care settings.\n\nDespite recommendations for greater involvement of relatives, support for this group is often uneven and poorly coordinated across healthcare sectors. Relatives frequently experience lack of overview, limited guidance, and unclear expectations regarding their role. These challenges may increase caregiver burden and negatively affect both relatives' well-being and the continuity of care.\n\nThe PIRe 2.0 study aims to further test, and implement a structured intervention to support systematic involvement of relatives of people with ABI or MBT across hospital and community rehabilitation services. The intervention is designed as a \"caregiver compass\" that helps relatives understand their role, clarify their needs and wishes for involvement, and gain better overview of the care pathway.\n\nPIRe 2.0 is delivered through a stepped-care model, which allows the level of support to be adjusted over time based on each relative's level of burden and support needs. All relatives receive basic information and screening for caregiver burden using the 4-item Zarit Burden Interview (ZBI-4). Relatives who show signs of increased burden are offered additional support in steps, ranging from structured conversations with nurses to extended cross-sector coordination and specialized support for relatives with high or complex needs. Decisions about stepping up or down are based on both screening results and clinical assessment to ensure flexibility and person-centered care.\n\nThe study includes two groups of relatives: an intervention group receiving support through the PIRe stepped-care model, and a control group receiving usual care only. A total of 160 relatives will participate. Data are collected at baseline, at transitions between hospital and community care, and three to six months after the intervention.\n\nThe primary outcome is change in caregiver burden, measured with the Caregiver Burden Scale (CBS). Secondary outcomes include relatives' roles and responsibilities, perceived support and involvement in care, and mental well-being, assessed using validated patient-reported outcome measures.\n\nIn addition to evaluating the effect of the intervention, the study examines how the PIRe model can be implemented and sustained in everyday practice across healthcare sectors. The results are expected to show whether a structured, stepped-care approach can reduce caregiver burden, improve coordination between hospital and community services, and support more coherent and secure care pathways for people with ABI or malignant brain tumor and their relatives.",[239,29,240,241,242,243,244],"Brain Injuries, Acute","Brain (Nervous System) Cancers","Traumatic Brain Injuries","Glioblastom WHO Grade 4","Glioblastoma (GBM)","Stroke",[246,247,248,249,250,251,252,253,254,255],"Acquired brain injury","Malignant brain tumor","Relatives","Caregiver Burden","Involvement","Communication","Care transitions","Rehabilitation","Implementation","Stepped-care","2026-05-15",{"date":197,"type":41},{"date":259,"type":21},"2026-10-01",{"date":261,"type":21},"2029-09-30",{"name":263,"class":48},"Rigshospitalet, Denmark",{"id":265,"slug":4,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100633849","NCT07532031","APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas","Characterization of Peri-tumoral Microenvironment in High-grade Gliomas Through the Combined Use of APT-weighted Imaging and Diffusion MRI","APT-HGG","Inclusion Criteria:\n\n1. Adult patients (both male and female, \\>= 18 years old)\n2. Previously acquired MRI suggestive for the presence of high-grade glioma\n3. Treatment-naïve status, defined as no prior surgical, radiotherapeutic, or systemic oncological treatment for the index brain lesion.\n4. Indication for biopsy or tumor resection\n5. Willingness to participate to the study and ability to sign informed consent\n\nExclusion Criteria:\n\n1. Pregnancy (to be excluded through a human chorionic gonadotropin pregnancy test performed on urine or serum when childbearing potential) and \u002F or lactation.\n2. Contraindications to MRI because of:\n\n   I. Claustrophobia II. Presence of metallic objects or implanted medical devices in body (i.e., cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants) III. Sickle cell disease IV. Renal failure or reduced renal function, as determined by Glomerular Filtration Rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m\\^2 based on a serum creatinine level obtained within 40 days prior to registration\n3. Presence of any other co-existing condition (such as serious systemic illness, including uncontrolled intercurrent infection, uncontrolled malignancy, significant renal or hepatic disease, or psychiatric\u002Fsocial situations) which might, in the judgment of the investigator, increase the risks to the subject or limit compliance with study requirements\n4. Inability to undergo surgical procedures\n5. Severe hepatic impairment, defined as the presence of two or more of the following parameters (assessed within 40 days): bilirubin ≥3 mg\u002FdL, albumin \\\u003C2.8 g\u002FdL, International normalized ratio \\>2.3 with no history of anticoagulant therapy, platelet count \\\u003C 100 109\u002FL, AST ≥ 400 U\u002FL, ALT ≥400 U\u002FL, presence of ascites.",{"count":272,"type":21},20,"High-grade gliomas are the most common primary malignant brain tumors and are characterized by infiltration of the surrounding brain tissue beyond the visible tumor margins. This infiltrative growth represents a major challenge for treatment planning and contributes to tumor recurrence. Conventional magnetic resonance imaging (MRI) is limited in its ability to distinguish tumor infiltration from non-tumoral changes such as vasogenic edema in the peri-tumoral region.\n\nThis prospective single-center observational study aims to improve the characterization of the peri-tumoral microenvironment in patients with suspected high-grade gliomas using advanced MRI techniques, including amide proton transfer-weighted (APTw) imaging and diffusion tensor imaging (DTI). These techniques provide complementary information about tissue composition and microstructure and may help identify areas of tumor infiltration that are not visible on conventional imaging.\n\nAPTw- and DTI-derived maps will be combined to generate imaging-derived maps describing the likelihood of tumor infiltration within the peri-tumoral region. These maps will be compared with histopathological findings obtained from tissue samples collected during biopsy or tumor resection performed as part of standard clinical care. Histological analyses will include assessment of tumor cellularity using hematoxylin and eosin staining and additional immunohistochemical markers routinely used in neuropathological evaluation. Patients will undergo routine clinical follow-up and the prognostic significance of the imaging-derived map will be assessed.\n\nThe overall goal of the study is to develop and validate imaging-based biomarkers capable of identifying infiltrated tissue within the peri-tumoral region. These findings may contribute to improved diagnostic accuracy and support future treatment planning strategies in patients with high-grade gliomas.",[275,143,29],"High-Grade Glioma",[277,278,279,280,143],"Amide Proton Transfer Imaging","Diffusion Tensor Imaging","Imaging Biomarkers","High-grade glioma","2026-04-08",{"date":283,"type":41},"2026-04-15",{"date":285,"type":21},"2026-04-01",{"date":287,"type":21},"2029-04",{"name":289,"class":48},"IRCCS Ospedale San Raffaele",{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":49},"100631346","NCT07499479","Picture Naming Decoding From Intraoperative Recordings","Picture Naming Decoding From Intraoperative Electrophysiological Recordings During Awake Brain Tumor Surgery.","Naming-Decoder","Inclusion Criteria:\n\n1. Patients 18 years of age or older.\n2. Patients with a brain tumor requiring surgery under \"awake\" conditions with intraoperative placement of ECoG electrodes at Lariboisière Hospital.\n\n3 -Patients with tumor locations close to language processing areas. 4 -Patients having given consent during the interview with the neurosurgeon.\n\nExclusion Criteria:\n\n1. Patients with severe cognitive impairments that would prevent understanding and performing the image-naming task,\n2. Patients with major psychiatric disorders that could affect their ability to participate in the research,\n3. Patients with inoperable tumors,\n4. Patients with tumor locations incompatible with safe or effective placement of ECoG electrodes,\n5. Females that are breastfeeding or females with childbearing potential with positive urine pregnancy test or not using adequate contraception,\n6. Patients unable to provide informed consent due to cognitive or language limitations,\n7. Patients who have any electrical stimulator or any active implanted medical device that uses high magnetic or electrical currents (e.g. patients with pacemaker defibrillator, neurostimulator, drugs pumps, retinal and cochlear device),\n8. Any wearable medical device that may cause troubles to the investigational devices and injuries to the participants,\n9. Patients with medical contraindications to general or local anesthesia required for surgery,\n10. Patients with an active infection or infectious skin lesions on the scalp,\n11. Patients with a current use or a recent history of illicit drug(s) use or alcohol abuse (defined as frequent or daily consumption of more than four alcoholic drinks per day),\n12. Patients with contraindications to any surgical procedure,\n13. Patients undergoing treatment with anticoagulants, platelet aggregation inhibitors, or non-steroidal anti-inflammatory drugs,\n14. Patients who decline to participate in the study,\n15. Any specially protected person: adults protected by law; persons hospitalized without their consent, at the request of a third party or ex officio; persons deprived of their liberty by a judicial decision,\n16. Participation in another interventional study or being in the exclusion period at the end of a previous study.","84 Years",{"count":272,"type":21},[24],"The clinical investigation evaluates whether speech can be decoded from neural activity recorded with cortical surface electrocorticography (ECoG) electrodes during awake brain tumor surgery. Neural signals and voice recordings are collected while patients perform a picture naming task as part of standard intraoperative mapping. The study assesses the ability of machine learning algorithms to predict the named item from intraoperative electrophysiological recordings.",[29],"2026-03-24",{"date":304,"type":41},"2026-03-30",{"date":283,"type":21},{"date":307,"type":21},"2030-10-15",{"name":309,"class":48},"Assistance Publique - Hôpitaux de Paris",{"id":311,"slug":4,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":49},"100628955","NCT07468370","Real Time Craniotomy Planning Using Mixed Reality","Investigation of Augmented Reality\u002FMixed Reality Viewer for Surgical Planning in Cranial Surgery","Brain Tumor Group Inclusion Criteria:\n\n* Diagnosis: Patients diagnosed with a brain tumor requiring surgical intervention.\n* Age: Adults aged 18 years and older.\n* Consent: Patients who are able to provide written informed consent and are willing to comply with study procedures.\n* Preoperative Imaging: Patients who have undergone standard of care preoperative imaging (e.g., MRI, CT) suitable for use with the Brainlab Mixed Reality Viewer.\n* Surgical Eligibility: Patients deemed eligible for craniotomy based on current clinical standards and the judgment of the attending neurosurgeon.\n\nBrain Tumor Group Exclusion Criteria:\n\n* Inability to Provide Informed Consent: Subject is unable to provide written informed consent due to cognitive impairment, language barriers, or other reasons that preclude them from understanding the study's requirements.\n* Emergency Surgery: Subject requires emergency craniotomy where there is insufficient time to perform preoperative planning with the Mixed Reality Viewer.\n* Concurrent Participation in Other Clinical Trials: Subject is currently enrolled in another clinical trial that could interfere with the results of this study or place additional burdens on the subject.\n* Unstable Clinical Condition: Subject has a medical condition that is unstable or severe enough to preclude safe participation in the study, as determined by the investigator (e.g., severe cardiac or respiratory conditions).\n\nSurvey Group Inclusion Criteria:\n\n* Hospital Personnel: Includes hospital personnel operating or assisting in the brain tumor resection surgeries where the study device is being utilized on an enrolled subject in the study. This includes the Investigators, Clinical Research Coordinator, OR Nurses, and Residents.\n* Age: Adults aged 18 years and older.\n* Consent: Hospital personnel who are able to provide written informed consent and are willing to complete the survey.\n\nSurvey Group Exclusion Criteria:\n\n* Inability to Provide Informed Consent: Hospital personnel is unable to provide written informed consent",{"count":317,"type":21},54,"This study is a prospective observational study designed to evaluate the effectiveness of Brainlab's Mixed Reality Viewer in enhancing the accuracy and efficiency of preoperative craniotomy planning. The study will be conducted at a single site with two enrollment groups. Group 1 has a target enrollment of 38 subjects. Group 2 has a target enrollment of 16 subjects. By observing the device's use during standard surgical procedures, we can accurately measure its impact on incision planning accuracy, time efficiency, and overall ease of use compared to traditional neuronavigation systems. This design allows for the collection of both quantitative and qualitative data, providing a robust assessment of the Mixed Reality Viewer's potential to enhance surgical outcome",[66,320,29,321],"Surgical Planning","Craniotomy Tumor Removal Surgery",[323,324,325],"mixed reality","craniotomy planning","tumor localization","2026-03-11",{"date":328,"type":41},"2026-03-12",{"date":330,"type":21},"2026-06",{"date":332,"type":21},"2027-06",{"name":334,"class":335},"Brainlab AG","INDUSTRY",{"id":337,"slug":4,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":362,"locationsCount":4},"100629163","NCT07471100","Neuromodulation-Induced Cortical Prehabilitation in High Grade Glioma Near the Motor Pathway: Cortical Plasticity Assessed by Navigated Transcranial Magnetic Stimulation (nTMS)","Neuromodulation-Induced-Cortical-Prehabilitation In High Grade Glioma Close To The Motor Pathway: Analysis Of The Cortical Brain Plasticity Through Navigated Transacranial Magnetic Stimulation","Inclusion Criteria:\n\n1. Age 18-80\n2. Suspect of High Grade Glioma in MRI\n3. Any case of cortical\u002Fsubcortical HGG radiologically close to Motor Pathway and, thus, where intraoperative monitoring assistance is usually required\n4. Preservation of motor function (at least ≥ 3 according to Medical Research Council classification)\n5. Signed informed Consent\n\nExclusion Criteria:\n\n1. Refusal to Study participation\n2. Multifocal\u002FBilateral Disease","80 Years",{"count":344,"type":21},63,[24],"The goal of this clinical trial is to learn whether Neuromodulation-Induced-Cortical-Prehabilitation (NICP)-using physical therapy (constraint-induced movement training, CIM) alone or combined with repetitive transcranial magnetic stimulation (rTMS)-can promote motor-cortex neuroplasticity before surgery in adults with high-grade gliomas near the motor pathway. It will also learn about the feasibility and safety of these prehabilitation strategies around the time of surgery. The main questions it aims to answer are:\n\n1. Does CIM (with or without rTMS) produce measurable motor-cortex plasticity from baseline to pre-surgery as assessed by neuronavigated TMS (nTMS)?\n2. Does adding rTMS to CIM lead to greater neuroplastic changes than CIM alone?\n3. What clinical, radiological, and neurophysiological outcomes are observed after surgery in participants who receive prehabilitation compared with controls?\n\nResearchers will compare standard care (control) vs CIM-based physical therapy vs CIM plus rTMS to see if these approaches induce preoperative neuroplastic changes that may support better surgical outcomes. Participants will:\n\n1. Be randomized to one of three groups: control, CIM physical therapy, or CIM + rTMS• Undergo nTMS motor mapping and excitability testing at baseline (T0) and the day before surgery (T1)\n2. Undergo planned tumor surgery (according to standard methods of care) and complete postoperative clinical, imaging, and neurophysiological follow-up assessments.",[29,27,348],"Glioma, High Grade",[350,351,352,353,354,355,356],"prehabilitation","neuromodulation","brain plasticity","cortical plasticity","rTMS","nTMS","physical therapy",{"date":358,"type":41},"2026-03-13",{"date":285,"type":21},{"date":361,"type":21},"2030-03-31",{"name":363,"class":48},"Azienda Sanitaria dell'Alto Adige",{"id":365,"slug":4,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":370,"maxAge":342,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":382,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":49},"100628315","NCT07460037","Chinese-Specific Speech Imagery Coding Using High-Density ECoG","Investigation of Chinese-Specific Speech Imagery Encoding and Decoding Using High-Density Electrocorticography","Inclusion Criteria:\n\n* Age between 20 and 80 years.\n* Ability and willingness to provide informed consent and comply with study procedures.\n* No severe preoperative emotional or consciousness disorders that would preclude participation in experimental tasks.\n* For patients undergoing intraoperative temporary high-density ECoG coverage: Patients with cerebral eloquent-area gliomas or refractory epilepsy undergoing awake craniotomy as part of standard clinical management.\n* For patients undergoing intraoperative temporary high-density ECoG coverage: Lesions involving or adjacent to eloquent brain areas including language, motor, or memory-related regions.\n* For patients undergoing intraoperative temporary high-density ECoG coverage: Mild mass effect without severe intracranial hypertension.\n* For patients undergoing intraoperative temporary high-density ECoG coverage: Preoperative language function largely preserved, with naming, reading, and language comprehension ≥80% of normal performance.\n* For patients undergoing permanent high-density ECoG implantation: Severe speech or language dysfunction caused by stroke, brain tumors, amyotrophic lateral sclerosis (ALS), or locked-in syndrome.\n* For patients undergoing permanent high-density ECoG implantation: No substantial improvement after 3-6 months of adequate rehabilitation and disease duration \\>12 months.\n* For patients undergoing permanent high-density ECoG implantation: Structural integrity of speech imagery-related cortices (ventral central lobule, supramarginal gyrus, superior temporal gyrus, middle temporal gyrus, middle frontal gyrus, and inferior frontal gyrus).\n* For patients undergoing permanent high-density ECoG implantation: Diagnosis of severe dysarthria or severe motor aphasia, with spontaneous speech score \\\u003C5\u002F20 on the Aphasia Battery of Chinese (ABC) and auditory comprehension ≥80% of normal levels.\n\nExclusion Criteria:\n\n* Significant mass effect with severe intracranial hypertension precluding awake craniotomy or electrode implantation.\n* Severe neurological dysfunction that would prevent participation in study procedures (except for speech or language impairment in the permanent implantation cohort).\n* Contraindications to MRI scanning or awake craniotomy, including incompatible implanted medical devices, severe claustrophobia, or obstructive sleep apnea syndrome.\n* Severe psychiatric disorders or cognitive impairment preventing participation in treatment or follow-up assessments (Mini-Mental State Examination score \\\u003C24).\n* Severe systemic medical comorbidities.\n* Pregnancy or lactation.\n* Refusal or inability to provide informed consent.","20 Years",{"count":372,"type":21},50,[24],"The goal of this study is to investigate whether high-density electrocorticography (ECoG) signals recorded from the surface of the brain can be used to decode neural representations of Mandarin Chinese speech features, including lexical tone, without requiring overt speech movements. The study focuses on the development and evaluation of decoding algorithms based on neural activity recorded during clinically indicated neurosurgical procedures.\n\nThe main questions it aims to answer are:\n\nCan high-density ECoG signals be decoded to reconstruct neural representations of Mandarin Chinese speech features, particularly lexical tone?\n\nCan neural activity recorded during silent auditory speech imagery be decoded to reconstruct tone-specific speech representations without actual articulation?\n\nThe study includes two groups of adult patients with neurological conditions who require cortical electrode placement as part of clinically indicated care:\n\nA intraoperative high-density ECoG temporary coverage group, enrolling approximately 50 patients with functional-area glioma or drug-resistant epilepsy who undergo awake neurosurgery with temporary high-density ECoG coverage for clinical functional mapping.\n\nA permanent high-density ECoG implantation group, enrolling approximately 10 patients with severe speech or language impairment caused by neurological conditions such as stroke, brain tumors, amyotrophic lateral sclerosis (ALS), or locked-in syndrome, who receive permanent high-density cortical electrode implantation for long-term monitoring.\n\nParticipants will:\n\nComplete preoperative clinical assessments as part of standard medical care, including brain imaging, language function evaluation, and routine neurological assessments\n\nUndergo clinically indicated awake neurosurgical procedures during which high-density ECoG electrodes are placed on the cortical surface for clinical functional localization\n\nPerform language-related tasks, such as listening to speech, imagining speech, and limited spoken responses, while brain electrical activity is recorded for approximately 20-30 minutes during surgery, without altering standard surgical procedures\n\nFor participants in the permanent implantation group, participate in long-term follow-up visits approximately every 2 weeks or monthly for up to 12 months after surgery, including evaluation of signal quality and research-related analysis and optimization of decoding algorithms\n\nAll surgical procedures involving temporary or permanent electrode placement are performed for clinical indications and have been approved through institutional ethical and scientific review. Participation in this study does not alter standard clinical care for the temporary recording group and does not require additional clinical procedures beyond routine treatment.\n\nThis research aims to support the long-term development of silent brain-to-speech communication technologies for individuals with severe speech or motor impairments and to improve understanding of how frontal, parietal, and temporal brain regions represent imagined speech in tonal languages such as Mandarin Chinese.",[376,377,378,379,244,29,380,381],"Aphasia","Dysarthria","ALS","Speech and Language Disorder","Epilepsies","locked-in Syndrome",[383,384,385,386,387],"speech imagery","speech production","Chinese Mandarin","neural encoding","speech decoding","2026-03-09",{"date":390,"type":41},"2026-03-10",{"date":392,"type":21},"2026-03-15",{"date":394,"type":21},"2028-12-31",{"name":396,"class":48},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":398,"slug":4,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":404,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":49},"100290953","NCT03067467","Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)","Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)","HPCIM","Inclusion Criteria:\n\n* Definitive diagnosis of brain tumors by imaging which demonstrates all kinds of brain malignancy, including glioma, meningioma, and brain metastases prior to any chemotherapy or radiation treatment.\n* 18-70 years of age\n* Ability to understand and the willingness to sign a written informed consent.\n* All races and ethnicities will be included; subjects must be able to read and speak the English language. Once the protocol is established, Spanish-speaking participants will be included.\n* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n\nExclusion Criteria:\n\n* Subjects who are receiving any other investigational agents.\n* Previous or current treatment by radiation or chemotherapy.\n* Concurrent illness including, but not limited to, ongoing or active infection, uncontrolled chronic diseases such as hypertension, lung disease, liver disease, kidney disease, diabetes, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Subjects who have a history of alcohol abuse or illicit drug use.\n* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants\n* Subjects who have contraindication to contrast enhanced MRI examination\n\nContraindications to MRI examination include:\n\n* Medically unstable\n\n  * Heart failure\n  * Severe LVOT outflow obstruction\n  * Unstable angina\n  * Child bearing\n  * Lactating\n* Any contraindication per MRI Screening Form including\n\n  * Implants contraindicated at 3T, pacemakers\n  * Implantable Cardioverter Defibrillator (ICD)\n  * Claustrophobia\n* Since each subject may be receiving a gadolinium-based contrast agent intravenously:\n\n  * eGFR ≤ 30 mL\u002Fmin\u002F1.73m2\n  * Sickle cell disease\n  * Hemolytic anemia",{"count":7,"type":21},"This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \\[1-13C\\]pyruvate MRSI.",[29],"2026-03-06",{"date":390,"type":41},{"date":410,"type":41},"2019-06-01",{"date":412,"type":21},"2026-12-31",{"name":414,"class":48},"University of Texas Southwestern Medical Center",{"id":416,"slug":4,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":49},"100607284","NCT07186556","Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention","Inclusion Criteria:\n\n1. Is currently between the ages of 18-39 years\n2. Their primary brain tumor was diagnosed at age 15-39 years\n3. Is 6 months to \\\u003C5 years post curative treatment\n4. Has been treated with chemotherapy and radiation, given most patients receive both therapies.\n5. Functional Assessment of Chronic Illness therapy (FACIT)-Fatigue ≤ 43. FACIT-Fatigue will be used as a screener because this 13-item scale can be completed relatively quickly in clinic\n6. Currently engage in \\\u003C150 minutes of PA and \\\u003C 2 sessions of muscle strengthening exercise per week (assessed by Godin Leisure-Time PA Questionnaire)\n7. Must be able to speak, write, and read English\n8. No exercise contraindication as assessed by screening with the Physical Activity Readiness Questionnaire PAR-Q+. In addition, participants' care teams will be notified of their participation in the study.\n9. Must be able to provide informed consent\u002Fassent.\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. Screen failure for exercise safety\n3. Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease\n4. Recent fracture or acute musculoskeletal injury that precludes ability to participate in supervised exercise training sessions\n5. History of underlying chronic disease, secondary malignances, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain\n6. Cognitive and\u002For major sensory deficits that would impede the completion of research activities and assessments as deemed by the clinical team.\n7. Self-report of pregnancy\n8. Prisoners\n9. Documented developmental disorders (e.g., Autism) or major psychotic illness (e.g., schizophrenia)","39 Years",{"count":422,"type":21},75,[24],"The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.",[147,426,29],"Fatigue","2026-03-02",{"date":429,"type":41},"2026-03-04",{"date":431,"type":41},"2025-09-09",{"date":433,"type":21},"2031-12-31",{"name":435,"class":48},"M.D. Anderson Cancer Center",{"id":437,"slug":4,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":442,"maxAge":84,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":460,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":473},"100622970","NCT07390539","B7-H3.CD28Z.CART in CNS Neoplasms","A Phase 1\u002F1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target","Pre-screening Inclusion Criteria:\n\n* Participants must have histologically and\u002For molecularly confirmed CNS embryonal tumor (see eligible tumor types below), OR ependymoma that is recurrent\u002Fprogressive following standard of care treatment.\n\n  --Eligible CNS embryonal tumor types include:\n  * Medulloblastoma\n  * Atypical Teratoid Rhabdoid Tumor (ATRT)\n  * Embryonal Tumor with Multilayered Rosettes (ETMR) Pineoblastoma\n  * Other CNS embryonal tumor types, at the discretion of the study chair (or designee)\n* Participants must have adequate pre-trial tumor material available to determine B7- H3 expression status. Tumor tissue from the most recent resection or biopsy of recurrent disease is preferred. If unavailable, tumor tissue from prior recurrences or from time of initial diagnosis is acceptable. Biopsies will not be performed for participation in this research trial or for research purposes.\n* Pre-screening IHC Consent: All participants ≥ 18 years of age must be able to give informed consent. For participants \\\u003C18 years of age, their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric participants will be included in age-appropriate discussion and written assent will be obtained for those ≥10 years of age, where appropriate. If a minor becomes of age during participation of this study, they will be asked to reconsent as an adult.\n\nInclusion Criteria:\n\n* Participants must have histologically and\u002For molecularly confirmed CNS embryonal tumor (see eligible tumor types below), OR ependymoma that is recurrent\u002Fprogressive following standard of care treatment.\n\n  --Eligible CNS embryonal tumor types include:\n  * Medulloblastoma\n  * Atypical Teratoid Rhabdoid Tumor (ATRT)\n  * Embryonal Tumor with Multilayered Rosettes (ETMR)\n  * Pineoblastoma\n  * Other CNS embryonal tumor types, at the discretion of the study chair (or designee)\n* B7-H3 expression: Demonstration of B7-H3 expression with H score greater than 100 by immunohistochemistry (IHC) is required.\n* Age: greater than or equal to two (2) years of age and less than or equal to 21 years of age. The first participant treated at each dose level within each stratum (Standard Risk and High Risk) will be ≥ 6 years of age when feasible.\n* Disease status: Participants must have evaluable disease in the central nervous system to be eligible. Evaluable disease includes either measurable OR non-measurable disease, defined as follows:\n\n  --Measurable disease (contrast-enhancing or non-enhancing tumor)\n  * Clearly defined lesional margins with two perpendicular diameters of at least 10mm, OR\n  * At least two times (in both perpendicular diameters) the MRI slice thickness, plus the interslice gap\n\n    --Non-measurable disease (tumor that is too small to be accurately measured)\n  * Lesion that is measurable in only one perpendicular dimension, OR\n  * Lesion that is less than 10mm in at least one perpendicular dimension, OR\n  * Lesion that is less than two times the MRI slice thickness, plus the interslice gap\n  * Note: Leptomeningeal (LM) disease is considered non-measurable but evaluable.\n* Performance status: Karnofsky performance status ≥60% for participants ≥16 years of age and Lansky performance status ≥60% for participants \\\u003C16 years of age (see APPENDIX A PERFORMANCE STATUS CRITERIA). NOTE: Participants with neurologic deficits must have a stable neurologic exam for seven (7) days prior to enrollment. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n* Life expectancy of greater than 12 weeks\n* Prior therapy: Participants must have received prior standard of care therapy, including maximal safe surgical resection, radiation therapy and\u002For standard chemotherapy, and is recovered from all acute treatment-related toxicities (defined as ≤ Grade 1 or stable) from all prior therapy before entering this study There is no upper limit to the number of prior therapies allowed, but must have received all standard curative options for their tumor type.\n* Participants must meet the following washouts prior to enrollment:\n\n  * Radiation therapy - Participants must have had their last fraction of:\n\n    ---Craniospinal irradiation, whole brain radiation therapy, or radiation therapy to \\>50% of the pelvis or spine \\>28 days prior to enrollment\n\n    ---Focal irradiation (small port) \\>14 days prior to enrollment\n  * At least 14 days since any prior cytotoxic chemotherapy\n  * At least 7 days since any biologic antineoplastics, tyrosine kinase inhibitor, targeted agent\n  * At least 21 days or 5 half-lives (whichever is shorter) since any investigational antineoplastic or disease-directed agent (but at least 28 days from prior investigational antineoplastic vaccine therapy)\n  * At least 21 days since any monoclonal antibody therapy\n  * At least 90 days since any systemic inhibitor\u002Fstimulatory immune checkpoint therapy\n  * At least 28 days from prior autologous stem cell transplantation, with no ongoing toxicities\n  * At least 14 days after peg-filgrastim and 7 days for hematopoietic growth factor support\n* Steroid use: Must not require concurrent systemic steroid therapy, although physiologic corticosteroid replacement therapy for management of pituitary\u002Fadrenal insufficiency and\u002For topical administration (e.g. inhaled or dermatologic) is allowed. Use of topical, ocular, intranasal, or inhaled corticosteroids are permitted per PI\n\ndiscretion.\n\n* Participants must have adequate organ function, as defined below\n\n  --Adequate bone marrow function\n  * Hemoglobin ≥ 8 g\u002FdL\n  * Absolute neutrophil count (ANC) ≥ 1000 cells\u002FuL\n  * Absolute lymphocyte count (ALC) ≥ 150 cells\u002FuL\n  * Platelets ≥100,000\u002FuL (unsupported, defined as no platelet transfusion within 4 days)\n* Adequate renal function defined as creatinine within normal limits for age OR creatinine clearance (as estimated by Cockcroft Gault Equation for participants ≥ 18yo and Bedside Schwartz for participants \\\u003C18yo) ≥70mL\u002Fmin\n\n  * Maximum Serum Creatinine mg\u002FDL ---6 months to 1 year Male 0.5 Female 0.5 ---1 to \\\u003C 2 years Male 0.6 Female 0.6 ---2 to \\\u003C 6 years Male 0.8 Female 0.8\n\n    * 6 to \\\u003C 10 years Male 1 Female 1\n    * 10 to \\\u003C 13 years Male 1.2 Female 1.2\n    * 13 years to \\\u003C 16 years Male 1.5 Female 1.4\n\n      * 16 years Male 1.7 Female 1.4\n* Adequate hepatic function\n\n  * Serum ALT\u002FAST ≤3.0 upper limit of normal (ULN)\n  * Total bilirubin ≤1.5mg\u002FdL, except in subjects with confirmed Gilbert's syndrome\n* Adequate cardiac function\n\n  --Ejection fraction ≥50% or fractional shortening ≥28%, measured by echocardiography\n* Adequate pulmonary function\n\n  * No evidence of dyspnea at rest\n  * Pulse oximetry \\>92% whilst breathing room air\n* Adequate neurologic function\n\n  * Participants with seizure disorders on anticonvulsants may be enrolled if seizures are well controlled (no seizure activity within 7 days prior to enrollment)\n  * Nervous system disorders (CTCAE v6.0) resulting from prior therapy must be ≤ Grade 2, with the exception of decreased tendon reflex (DTR; any Grade eligible). Participants with neurological deficits should be stable for a minimum of 7 days prior to enrollment. (A baseline detailed neurological exam should clearly document the neurological status of the participant prior at enrollment).\n* Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization are not considered to be of childbearing potential)\n* Participants of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for one year after receiving the preparative lymphodepletion regimen, or for as long as B7- H3.CD28Z.CART cells are detectable in peripheral blood or CSF, whichever is later.\n* Participant or parent of participant or legally recognized representative must be able to sign a written informed consent document. Pediatric participants will be included in age-appropriate discussion and written assent will be obtained for those ≥10 years of age, where appropriate.\n\nExclusion Criteria:\n\n* Participants with bulky tumor are ineligible. Bulky tumor is defined as:\n\n  * Tumor with diameter of \\>5cm in one dimension on T2\u002FFLAIR sequence\n  * Tumor with evidence of clinically significant midline shift or uncal herniation\n  * Tumor that, in opinion of the site investigator, shows significant mass effect in either the brain or spine\n* Participants with clinical or radiological evidence of brain herniation.\n* Participants who have received other B7-H3 targeted cellular therapies. Other prior cellular therapies are eligible, including immune checkpoint inhibition and vaccine therapy. These prior therapies should be discussed with the study chair (or designee) prior to participant enrollment.\n* Concurrent illness\n\n  * Participants with any prior immunodeficiency or history of autoimmune disease requiring systemic steroids\u002F immunosuppressive medication\u002F disease-modifying agents within the last two (2) years.\n  * Uncontrolled (Grade 3) bacterial, viral, fungal, or other infection.\n  * Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and\u002For nucleic acid testing.\n  * Evidence of severe or uncontrolled systemic disease (e.g. Grade 3 significant cardiac, pulmonary, hepatic, renal or other organ dysfunction) that in the judgement of the principal investigator is likely to interfere with assessment of safety or efficacy of the investigational regimen and its requirements.\n  * Known sensitivity or allergy to any of the agents\u002Freagents used in this study (i.e. DSMO, cyclophosphamide, fludarabine)\n  * History of severe hypersensitivity reaction to compounds of similar chemical or biologic compositions to any agent used in the study or in the manufacturing of cells.\n* Concomitant medications\n\n  * Current systemic corticosteroid therapy\n  * Note, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency will be allowed.\n  * Participants who are receiving any other anti-cancer or investigational drug therapy are ineligible.\n  * Participants who have received the last vaccination of a live vaccine ≤ 30 days prior to the start of treatment are ineligible.\n  * Ongoing use of dietary supplements, alternative therapies or extreme diets, or any medication not approved by the study chair (or designee).\n* Any other condition which in the principal investigator's opinion makes the individual clinically unsuitable to participate in this trial, or which would jeopardize compliance with the protocol, or would make it difficult to interpret adverse events or study data.","2 Years",{"count":444,"type":21},70,[138],"The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors. Recurrent\u002Frecurred means a tumor that has gone away and then came back. This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells. B7-H3 is a protein that is over-expressed on many tumor cells, making it a good target for cancer cell therapy.\n\nThe names of the study investigational therapies involved in this study are:\n\n* Fludarabine (a type of chemotherapy)\n* Cyclophosphamide (a type of chemotherapy)\n* B7-H3 CAR T cells (a type of cellular therapy)",[448,116,449,450,29,451,452,453,454,455,456,457,458,459],"Central Nervous System Neoplasms","Brain Tumor, Recurrent","Brain Tumor, Pediatric","Medulloblastoma","Medulloblastoma, Childhood","Medulloblastoma, Adult","Medulloblastoma Recurrent","Ependymoma","Atypical Teratoid\u002FRhabdoid Tumor","Embryonal Tumor With Multilayered Rosettes","Pineoblastoma","Leptomeningeal Disease",[448,116,450,461,462,451,452,453,454,455,456,463,458,459],"Brain Tumor, Adult","Brain Tumor Recurrent","Embryonal Tumor with Multilayered Rosettes","2026-01-28",{"date":466,"type":41},"2026-02-05",{"date":468,"type":21},"2026-07",{"date":470,"type":21},"2032-08-31",{"name":472,"class":48},"Robbie Majzner",2,{"id":475,"slug":4,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100621875","NCT07376304","Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI","Optimization of Intraoperative Ultrasound Use in Brain Tumor Surgery Through Artificial Intelligence-Based Techniques","BrainUS-AI","Inclusion criteria:\n\n* Age ≥ 18 years.\n* Scheduled for craniotomy and resection of a brain tumor with ioUS planned as part of the standard surgical workflow.\n* Preoperative MRI available for surgical planning.\n* Ability to obtain informed consent from the patient or legal representative.\n\nExclusion criteria:\n\n• Inadequate ioUS image acquisition due to technical failure or intraoperative complications unrelated to the tumor.",{"count":482,"type":21},100,[484],"PHASE3","Intraoperative ultrasound is a versatile, low-cost imaging tool that has been shown to improve safety and efficacy in brain tumor surgery. However, its widespread adoption remains limited due to operator dependency, the complexity of image interpretation, the presence of artifacts, and a restricted field of view.\n\nThis project aims to prospectively evaluate, in a multicenter and non-randomized setting, a prototype real-time deep learning-based segmentation model for brain tumor delineation in intraoperative ultrasound. The model is designed to facilitate the identification of tumor tissue during surgery, potentially enhancing intraoperative decision-making and surgical precision.\n\nBy increasing the precision and accessibility of ioUS, this innovation is expected to enable safer and more complete resections, with the potential to improve both survival and quality of life for patients with brain tumors.",[29],[193,195,488,489,490,491,492,493,494],"glioblastoma","low-grade glioma","high-grade glioma","ious","computer vision","AI","ultrasound","2026-01-22",{"date":497,"type":41},"2026-01-29",{"date":499,"type":21},"2026-03",{"date":501,"type":21},"2028-06",{"name":503,"class":48},"Hospital del Rio Hortega",{"id":505,"slug":4,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":512,"conditions":513,"keywords":519,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":49},"100610247","NCT07225101","Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures","Inclusion Criteria:\n\n* Elective or emergent surgical approaches for cranial or spine neurosurgical approaches, requiring sutures for wound closure, requiring multilayer wound closure\n\nExclusion Criteria:\n\n* Patients with prior surgical wound dehiscence or infection\n* Patients with allergy to suture material",{"count":235,"type":21},[511],"PHASE4","This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.",[514,29,515,516,517,518],"Wound Closure","Spine","Neurovascular","Hemorrhagic Stroke, Intracerebral","Traumatic Brain Injury",[520,521,522,193,523,524,525,526,527],"Superficial surgical site infection","Suture material","Wound closure techniques","spine","spine trauma","neurosurgery","hemorrhagic stroke","traumatic brain injury","2025-11-03",{"date":530,"type":41},"2025-11-05",{"date":532,"type":41},"2025-11-01",{"date":412,"type":21},{"name":535,"class":48},"University of Michigan",{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":542,"enrollmentInfo":543,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":545,"conditions":546,"keywords":550,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":473},"100608184","NCT07198256","AI-assisted Diagnosis of Malignant Brain Tumors","Research on AI-assisted Diagnosis of Common Malignant Brain Tumors Based on Magnetic Resonance Imaging","Inclusion Criteria:\n\n* Patients diagnosed with glioma, brain metastases, and brain lymphoma by pathology, with the patient being at least 18 years old; preoperative MRI was complete.\n\nExclusion Criteria:\n\n* Poor image quality; history of previous brain surgery or radiotherapy; accompanied by other intracranial lesions.","100 Years",{"count":544,"type":21},3000,"This study aims to establish a large-scale, multi-center MRI database for malignant brain tumors. It will develop an artificial intelligence system for the segmentation and classification of multiple subtypes of brain tumors (including glioma, metastatic tumor and lymphoma et al.) using deep learning technology. This will address the issues of small sample sizes and limited classification performance in existing methods, thereby improving the accuracy of non-invasive preoperative diagnosis, reducing the need for biopsies, and having significant clinical translational value.",[547,548,549,29],"Gliomas","Brain Metastases, Adult","Lymphoma",[193,195,551,552,553,554],"brain metastases","lymphoma","magnetic resonance imaging","artificial intelligence","2025-09-22",{"date":557,"type":41},"2025-09-30",{"date":559,"type":41},"2025-09-01",{"date":394,"type":21},{"name":396,"class":48},{"id":563,"slug":4,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":577,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":49},"100606728","NCT07179328","Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy","Assessment of Safety and Feasibility of Focused Ultrasound Next Generational Dome Helmet Mediated Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy","Inclusion Criteria:\n\n1. Age between 18 and 85 years, inclusive.\n2. Able and willing to provide written informed consent.\n3. Diagnosis of Glioblastoma by histology or molecular markers based on WHO 2021 classification.\n4. Previously undergone a maximal safe surgical resection and completed concurrent, standard-of-care RT and TMZ without any complications and deemed eligible for the maintenance phase of TMZ treatment.\n5. Tumor or tumor resection cavity is clearly defined on screening MRI scans.\n6. Karnofsky Performance Score rating 70-100.\n7. American Society of Anesthesiologists (ASA) physical status score of 1-3.\n8. Life expectancy of at least 3 months and able to attend all study visits.\n\nExclusion Criteria:\n\n1. Patients presenting with the following imaging characteristics:\n\n   i. Following steroid treatment, brain edema and\u002For mass effect that causes midline shift or shift in wall of the third ventricle of more than 10 mm.\n\n   ii. Evidence of recent (less than 2 weeks) intracranial hemorrhage. iii. Calcifications in the FUS sonication beam path in the event system tools cannot tailor the treatment around these calcification spots.\n2. The sonication pathway to the tumor involves:\n\n   i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.\n\n   ii. Clips or other metallic implanted objects in the skull or the brain, except shunts.\n3. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).\n4. Patients requiring increasing doses of corticosteroids.\n5. Patient receiving bevacizumab (Avastin) therapy.\n6. Patients with ≥25% increase in volume of contrast enhancement at time of assessment for study enrollment, compared with their first postoperative MRI. This cut-off is used to differentiate between pseudoprogression (which can occur following both radiation and TMZ therapy) and true tumor progression. This will be further ascertained through a discussion between the study neurosurgeons and radiologists.\n7. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, and focal irradiation with brachytherapy, stereotactic radiosurgery, and laser interstitial thermotherapy. These regimens have been shown to cause contrast enhancement in the resection cavity boundary, which can be difficult to differentiate from true tumor recurrence.\n8. Cardiac disease or unstable hemodynamics including:\n\n   i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction \\\u003C50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.\n9. Severe hypertension (diastolic blood pressure (DBP) \\> 100 on medication).\n10. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment).\n11. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.\n12. Abnormal level of platelets (\\\u003C 100,000) or INR \\> 1.3.\n13. Documented cerebral infarction within the past 12 months.\n14. TIA in the last 1 month.\n15. Cerebral or systemic vasculopathy.\n16. Insulin-dependent diabetes mellitus that is not well-controlled or that in the Investigator's opinion precludes participation in the study.\n17. Known sensitivity to gadolinium-DTPA.\n18. Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.\n19. Contraindications to MRI such as non-MRI-compatible implanted devices, unable to tolerate an MRI due to for instance pain or claustrophobia, untreated, uncontrolled sleep apnea.\n20. Positive pregnancy test (for pre-menopausal women).\n21. Known life-threatening systemic disease.\n22. Severely impaired renal function with estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2 and\u002For on dialysis.\n23. Right to left or bi-directional cardiac shunt.\n24. Previous full course of chemotherapy for GBM (at the discretion of investigator).\n25. Previous radiotherapy.\n26. Allergy to eggs or egg products.\n27. Subjects with evidence of cranial or systemic infection.\n28. Subjects with chronic pulmonary disorders.\n29. Subjects with a history of drug allergies, asthma or hay fever, and multiple allergies, in particular subjects with a history of anaphylaxis.\n30. Subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation, or QT prolongation observed on screening ECG (QTc \\> 450 for men and \\>470 for women).\n31. Subjects with evidence of Hepatitis B virus infection\u002Fcarrier state.\n32. Liver injury as indicated by liver function tests that in the Investigator's opinion precludes participation in the study.","85 Years",{"count":20,"type":21},[138],"The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM) undergoing the maintenance phase of the standard \"Stupp protocol\".\n\nParticipants will:\n\n* Undergo repeated FUS BBB disruption treatments during the maintenance phase of temozolomide (TMZ) chemotherapy.\n* Receive intravenous ultrasound contrast (DEFINITY®) prior to each FUS session to facilitate targeted BBB disruption.\n* Undergo serial MRI scans and clinical assessments to evaluate safety and the extent of BBB opening.\n* Provide blood samples (and tumor tissue if available) for biomarker analysis related to BBB permeability, tumor presence, and treatment response.\n* Be followed for progression-free survival (PFS) and overall survival (OS) during routine neuro-oncology visits until end of life.",[573,142,574,575,576,27,29,146],"GBM","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme Glioma","HGG",[578,579,573,580,581,582,583,584,585,586,587],"Focused Ultrasound","FUS","TMZ","Temozolomide","blood-brain barrier disruption (BBBD)","MR-guided Focused Ultrasound (MRgFUS)","Glioblastoma multiforme","blood-brain barrier opening","Drug delivery","Chemotherapy delivery","2025-09-10",{"date":590,"type":41},"2025-09-17",{"date":592,"type":41},"2025-06-04",{"date":594,"type":21},"2027-11",{"name":596,"class":48},"Sunnybrook Health Sciences Centre",{"id":598,"slug":4,"hasResults":11,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":22,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":49},"100596716","NCT07049094","The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy","A Multicenter, Single-blind, Randomized Controlled Study on the Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ASA I-III\n* Scheduled for elective cranial surgery\n* Informed consent from the patient or legal representative\n\nExclusion Criteria:\n\n* Preoperative Glasgow score \\\u003C 15\n* Preoperative headache with NRS ≥ 4\n* Anticipated postoperative sedation or extubation difficulties requiring mechanical ventilation\n* Inability to understand the numerical rating scale (NRS)\n* Allergies or contraindications to amide local anesthetics, opioids, or NSAIDs\n* Long-term opioid or corticosteroid treatment (\\> 2 weeks)\n* History of drug abuse in the past 2 years\n* Daily alcohol consumption exceeding 3 standard doses\n* Mental or cognitive disorders affecting perioperative assessment\n* Contraindications for nerve blocks, including infection or tumors at the puncture site, diagnosed diabetic peripheral neuropathy, or inability to cooperate\n* Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (requiring dialysis preoperatively), or severe heart failure (METS \\\u003C 4)\n* Pregnant or breastfeeding women\n* History of craniotomy or pre-existing pathological pain conditions (e.g., migraines, trigeminal neuralgia)\n* Incisions for craniotomy extending beyond the area covered by the scalp nerve blocks\n* Participation in other clinical trials",{"count":604,"type":21},218,[511],"After undergoing craniotomy, 60% to 84% of neurosurgery patients experience moderate to severe acute pain, primarily in the first 48 hours. This pain is mostly superficial, affecting the muscles and soft tissues around the skull. Poor pain management can lead to complications such as restlessness, nausea, hypertension, increased intracranial pressure, and prolonged recovery, potentially resulting in chronic headaches.\n\nOpioids are commonly used to manage this pain but can cause significant side effects like sedation, nausea, and increased intracranial pressure, which can mask serious conditions. Non-opioid medications and scalp infiltration techniques can help but may not provide sufficient pain relief for the duration needed.\n\nCurrently, multimodal analgesia, particularly scalp nerve blocks, is advocated in neurosurgical recovery practices. These blocks are effective and simpler to perform, but the effects of long-acting local anesthetics, like bupivacaine, typically last only 24 hours. Since pain often persists longer than that, there is a need for better pain management strategies.\n\nLiposome bupivacaine is a new long-acting local anesthetic approved by the FDA, offering pain relief for up to 72 hours compared to regular bupivacaine's 8-hour duration. Its effectiveness has been confirmed in various nerve block procedures, but it has not been reported for scalp nerve blocks. This study aims to investigate whether liposome bupivacaine scalp nerve blocks can provide long-lasting postoperative pain relief, promote quicker recovery, and reduce complications in neurosurgery patients.",[29,608],"Cerebrovascular Disease",[221,610],"postoperative analgesia","2025-06-24",{"date":613,"type":41},"2025-07-03",{"date":615,"type":21},"2025-06-25",{"date":617,"type":21},"2027-12-31",{"name":619,"class":48},"Zhejiang University",{"id":621,"slug":4,"hasResults":11,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":628,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":49},"100586985","NCT06922500","Processed EEG for Monitoring of Anesthetic Depth in Intracranial Tumor Surgery","Anesthetic Depth Assessed by Processed EEG (pEEG) - a Comparison of Manual Total Intravenous Anesthesia and Target Controlled Anesthesia in Tumor Resection Via Craniotomy","Inclusion Criteria:\n\n* Elective craniotomy for tumor resection\n* Adult patient\n* Consent to participation\n\nExclusion Criteria:\n\n* Cognitive impact affecting infrmed consent\n* brain tumor planned for biopsy without resection Tumor localisation not permitting placement of pEEG electrodes.",{"count":627,"type":21},126,[24],"An important feature of neurosurgical anesthesia is early postoperative recovery of consciousness with minimal residual sedation. This is a key factor to enable early neurological assessment and early discovery of postoperative complications.\n\nThe goal of this single centre clinical trial is to compare propofol\u002Fremifentanil anesthesia delivered by manual total intravenous anesthesia (mTIVA) or target controlled infusion (TCI) for intracranial tumor resection via craniotomy. Anesthetic depth will be assessed by a simplified processed EEG (pEEG).\n\nThe main question is time spent within recommended pEEG- levels from anesthesia induction until end of surgery.\n\nSecondary questions are:\n\n* mean pEEG-level, time from end of surgery to consiousness,\n* peroperative propofol\u002Fremifentanil consumption\n* postoperative degree of sleepiness\n* awareness assessment\n\nParticipants are adults having have planned surgery for open resection of a brain tumor and will receive general anesthesia with propofol and remifentanil randomized to mTIVA or TCI. pEEG vill be blinded.\n\n* Participants will be asked to grade postoperative sleepiness using a specific scale\n* Follow up regarding awareness will be performed.",[29,631,632],"Processed EEG","Total Intravenous Anesthesia",[634],"total intavenous anesthesia, target controlled infusion, processed EEG, open resection of brain tumor,","2025-04-09",{"date":637,"type":41},"2025-04-10",{"date":639,"type":41},"2024-11-21",{"date":641,"type":21},"2027-07",{"name":643,"class":48},"Region Skane",{"id":645,"slug":4,"hasResults":11,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":651,"conditions":652,"keywords":654,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":663,"locationsCount":49},"100586984","NCT06922487","Assessment of Tiredness During Awake Resection of Intracerebral Tumors","Förekomsten av trötthet Vid Neurokirurgisk Vakenkirurgi","Inclusion Criteria:\n\n* Adult (\\>18 years old)\n* Elective supra or infratentorial tumor resection via craniotomy\n* Surgical need for awake surgery\n* Cognitive function allowing informed consent.\n\nExclusion Criteria:\n\n* Tumor resection without awake surgery\n* Morbid obesitas",{"count":20,"type":21},"Occasional patients with intracranial tumors need to have a planned awakening during surgery to avoid major disability from the tumor resection. During the awake part of the surgery an increasing degree of tiredness is observed. For the surgeon to plan the resection knowledge of the degree and speed of tiredness\u002Fsleepiness evolution is important.\n\nThe goal of this single center study is to use the \"Karolinska Sleepiness Scale\" during and after awake surgery for neurosurgical tumor resection to quantify the time available for surgical intervention.\n\nParticipants are adults having planned surgery for open resection of intracranial tumor with a planned awakening for assessment during surgery. Participants will be asked to grade postoperative sleepiness using the \"Karolinska Sleepiness Scale\".",[29,653],"Awake Surgery",[655,656,657],"open resection of intracranial tumor","awake surgery","sleepiness","2025-04-03",{"date":637,"type":41},{"date":661,"type":41},"2024-11-11",{"date":617,"type":21},{"name":643,"class":48},{"id":665,"slug":4,"hasResults":11,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":671,"targetDuration":673,"studyType":164,"phases":4,"briefSummary":674,"conditions":675,"keywords":677,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":473},"100584813","NCT06894238","Electroencephalogram Predicts Post-operative Delirium","Frontal-temporal EEG During Anesthesia Recovery Predicts Postoperative Delirium in Neurosurgery: a Single-center, Prospective, Observational Study","EPOD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned elective neurosurgical surgery\n* ASA physical status I-II\n* Signed informed consent\n\nExclusion Criteria:\n\n* Known neurological or psychiatric disorders (e.g., epilepsy, Parkinson's disease)\n* Preoperative cognitive impairment (MMSE score \\\u003C 24)\n* Long-term use of central nervous system drugs (e.g., antidepressants, antipsychotics)\n* Language barriers\n* History of craniotomy within the last 12 months\n* Inability to place frontal-temporal electrodes due to conditions such as frontal skin injury, severe agitation, or a coronal incision for surgery\n* Pregnant or breastfeeding women",{"count":672,"type":21},137,"30 Days","The goal of this observational study is to investigate the predictive value of sub-hairline electroencephalography (EEG) during anesthesia recovery for postoperative delirium (POD). The main question to be answered is:\n\n* Can sub-hairline EEG measured during anesthesia recovery serve as a reliable predictor of POD? Adult patients undergoing elective craniotomy and admitted to the ICU will be enrolled. Sub-hairline EEG will be monitored until ICU discharge.",[66,676,29],"Delirium - Postoperative",[678,679,680,681,682,683,684],"Postoperative delirium","electroencephalography","neurosurgical patients","Sub-hairline EEG","Confusion Assessment Method for ICU (CAM-ICU)","Delirium Observation Screening Scale (DOSS)","Fluctuating Mental Status Evaluation (FMSE)","2025-03-18",{"date":687,"type":41},"2025-03-25",{"date":689,"type":41},"2025-03-01",{"date":691,"type":21},"2026-05-01",{"name":693,"class":48},"Beijing Sanbo Brain Hospital",""]